Ex-pharma CEO Shkreli is getting new lawyers

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated.

Martin Shkreli (C), CEO of Turing Pharmaceutical, is brought out of 26 Federal Plaza by law enforcement officials after being arrested for securities fraud on December 17, 2015 in New York City. Shkreli gained notoriety earlier this year for raising the price of Daraprim, a medicine used to treat the parasitic condition of toxoplasmosis, from $13.50 to $750 though the arrest that happened early this morning does not involve that price hike. (Photo by Andrew Burton/Getty Images)

NEW YORK (AP) — The pharmaceutical executive reviled for price-gouging is changing lawyers.

The outgoing legal team for former pharmaceutical company CEO Martin Shkreli notified a Brooklyn judge this week.

Shkreli told The New York Times in an email that the change is not related to his weekend TV interview. He called that “a dumb theory.”

He told Fox 5 News in New York that “the government’s case is fictitious.” He also took issue with assertions that he’s the world’s “most hated man.”

The 32-year-old former hedge fund manager has pleaded not guilty to securities fraud and conspiracy. Prosecutors say Shkreli lost investors’ money through bad trades, then looted the pharmaceutical company to pay them back.

Shkreli was already reviled because the drug company raised the price of a life-saving medicine from $13.50 to $750 per pill.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

Notice: you are using an outdated browser. Microsoft does not recommend using IE as your default browser. Some features on this website, like video and images, might not work properly. For the best experience, please upgrade your browser.